Home » Pharmacology » Enzymes » Kinases » MAPK » p38 MAPK » VX 702

VX 702

Cat No. 3916

Price and Availability

For VX 702 pricing & availability please select your country from the drop down menu:
Submit

Chemical Name: 6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-dif luorophenyl)-3-pyridinecarboxamide

Biological Activity

Orally active, ATP-competitive inhibitor of p38α MAPK; also inhibits p38β (K_D values are 3.7 and 17 nM respectively).

Technical Data

M.Wt:

404.32

Formula:

C₁₉H₁₂F₄N₄O₂

Solubility:

Soluble to 100 mM in DMSO

Purity:

>98 %

Storage:

Store at +4°C

CAS No:

[479543-46-9]

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis and MSDS.

Resources

Certificate of Analysis / MSDS

Certificate of Analysis: View current batch

Material Safety Data Sheet: View current batch

References

Damjanov et al (2009) Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis. Arthrit.Rheumat. 60 1232. Ding (2006) Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr.Opin.Investig.Drugs 7 1020. Goldstein et al (2010) Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. 53 2345.

If you know of a useful citation for this product please let us know.

View Related Products by Target

MAPK

p38 MAPK

Keywords: VX 702, VX702, orally, active, p38α, p38alpha, p38a, p38β, p38beta, p38b, inhibitors, MAPK, Signaling, Signalling, Mitogen-Activated, Protein, Kinases